Armodafinil

Armodafinil is a 2-[(diphenylmethyl)sulfinyl]acetamide that has R configuration at the sulfur atom. Like its racemate, modafinil, it is used to treat sleeping disorders including narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. Peak concentration in the blood later occurs later following administration than with modafinil, so it is thought that armodafinil may be more effective than modafinil in treating people with excessive daytime sleepiness. Among its listed roles, it functions as a central nervous system stimulant and a eugeroic. It is an enantiomer of a (S)-modafinil. Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007. It is grouped under the following drug class(es): Neurotransmitter agents and Psychotropic agents. Its therapeutic use is listed as central nervous system (CNS) agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Nuvigil, (R)-Modafinil and Armodafinilum. It is listed as a controlled drug substance (Schedule IV). Its PubChem CID is 9690109.

CAS No 112111-43-0
Molecular Formula C15H15NO2S
Molecular Weight 273.35 g/mol
Synonyms 2-[(R)-benzhydrylsulfinyl]acetamide

Frequently Asked Questions